Tanya Siddiqi, M.D.

• Tam CS, Opat S, D'Sa SP, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan SP, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby EN, Matous JV, Motta M MD, Siddiqi T, Tani M, Trnĕný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Wu B, Yu Y, Shen Z Dr, Chan WY, Schneider J, Allewelt H, Cohen A, Dimopoulos MA. Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenström Macroglobulinemia. Blood Adv. 2024 Feb 5:bloodadvances.2023010906. doi: 10.1182/bloodadvances.2023010906. Epub ahead of print. PMID: 38315878. 
• Borogovac A, Siddiqi T. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies. Semin Hematol. 2024 Jan 5:S0037-1963(24)00003-9. doi: 10.1053/j.seminhematol.2024.01.001. Epub ahead of print. PMID: 38290860.
• Reyes A, Siddiqi T. Targeting BCL2 pathways in CLL: a story of resistance and ingenuity. Cancer Drug Resist. 2023 Nov 27;6(4):828-837. doi: 10.20517/cdr.2023.97. PMID: 38263980; PMCID: PMC10804389.
• Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, Abramson JS, Arnason J, Ghosh N, Mehta A, Andreadis C, Solomon SR, Kostic A, Dehner C, Espinola R, Peng L, Ogasawara K, Chattin A, Eliason L, Palomba ML. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. J Clin Oncol. 2023 Dec 10:JCO2302214. doi: 10.1200/JCO.23.02214. Epub ahead of print. PMID: 38072625.
• Siddiqi T. Update on the CAPTIVATE trial of ibrutinib plus venetoclax. Clin Adv Hematol Oncol. 2023 Dec;21(12):654-657. PMID: 38039059.
• Jain N, Croner LJ, Allan JN, Siddiqi T, Tedeschi A, Badoux XC, Eckert K, Cheung LWK, Mukherjee A, Dean JP, Szafer-Glusman E, Seymour JF. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res. 2024 Feb 1;30(3):498-505. doi: 10.1158/1078-0432.CCR-22-3934. PMID: 37955424; PMCID: PMC10831330.
• Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Dehner C, Kim Y, Ogasawara K, Kostic A, Siddiqi T. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024 Feb 1;143(5):404-416. doi: 10.1182/blood.2023020854. PMID: 37890149.
• Dimopoulos MA, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Chan WY, Schneider J, Allewelt H, Patel S, Cohen A, Tam CS. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol. 2023 Jul 21: JCO2202830. doi: 10.1200/JCO.22.02830. Epub ahead of print. PMID: 37478390.
• Lam V, Roleder C, Liu T, Bruss N, Best S, Wang X, Phillips T, Shouse G, Berger AJ, Alinari L, Wang L, Siddiqi T, Pennock ND, Danilov AV. T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia. Mol Cancer Ther. 2023 Jul 6: MCT-22-0762. doi: 10.1158/1535-7163.MCT-22-0762. Epub ahead of print. PMID: 37420267.
• Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 Jun 5: S0140-6736(23)01052-8. doi: 10.1016/S0140-6736(23)01052-8. Epub ahead of print. PMID: 37295445.
• Allan JN, Flinn IW, Siddiqi T, Ghia P, Tam CS, Kipps TJ, Barr PM, Elinder Camburn A, Tedeschi A, Badoux XC, Jacobs R, Kuss BJ, Trentin L, Zhou C, Szoke A, Abbazio C, Wierda WG. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. Clin Cancer Res. 2023 Jul 14;29(14):2593-2601. doi: 10.1158/1078-0432.CCR-22-2779. PMID: 37282671; PMCID: PMC10345960.
• Wu Y, Jin M, Fernandez M, Hart KL, Liao A, Ge X, Fernandes SM, McDonald T, Chen Z, Röth D, Ghoda LY, Marcucci G, Kalkum M, Pillai RK, Danilov AV, Li JJ, Chen J, Brown JR, Rosen ST, Siddiqi T, Wang L. METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL. Blood Cancer Discov. 2023 May 1;4(3):228-245. doi: 10.1158/2643-3230.BCD-22-0156. PMID: 37067905; PMCID: PMC10150290.
• Wang X, Chen C, Vuong D, Rodriguez-Rodriguez S, Lam V, Roleder C, Wang JH, Kambhampati S, Berger A, Pennock N, Torka P, Hernandez-Ilizaliturri F, Siddiqi T, Wang L, Xia Z, Danilov AV. Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia. Leukemia. 2023 Jun;37(6):1324-1335. doi: 10.1038/s41375-023-01889-x. Epub 2023 Apr 8. PMID: 37031300; PMCID: PMC10244170.
• Lee K, Iukuridze A, He T, Bosworth A, Lindenfeld L, Teh JB, Echevarria M, Albanese S, Atencio L, Bhandari R, Wong FL, Artz AS, Siddiqi T, Nikolaenko L, Zain J, Mei M, Shouse G, Popplewell LL, Herrera AF, Budde LE, Forman SJ, Armenian SH. Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy. J Natl Compr Canc Netw. 2023 Apr;21(4):373-382.e1. doi: 10.6004/jnccn.2022.7100. PMID: 37015335.
• Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff PJ, Flinn IW, Farooq U, Goy A, McSweeney P, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood. 2023 Feb 23: blood.2022018893. doi: 10.1182/blood.2022018893. Epub ahead of print. PMID: 36821768.
• Iyer P, Zhang B, Liu T, Jin M, Hart K, Zhang J, Song J, Chan WC, Siddiqi T, Rosen ST, Danilov A, Wang L. MGA deletion leads to Richter's transformation via modulation of mitochondrial OXPHOS. bioRxiv [Preprint]. 2023 Feb 8:2023.02.07.527502. doi: 10.1101/2023.02.07.527502. PMID: 36798339; PMCID: PMC9934534.
• Ujjani CS, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien SM, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling AL, Tu B, Sorensen T, Launchbury KM, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson PA. Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia. Blood Adv. 2022 Dec 14:bloodadvances.2022009164. doi: 10.1182/bloodadvances.2022009164. Epub ahead of print. PMID: 36516082.
• Ujjani CS, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien SM, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling AL, Tu B, Sorensen T, Launchbury KM, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson PA. Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia. Blood Adv. 2022 Dec 14:bloodadvances.2022009164. doi: 10.1182/bloodadvances.2022009164. Epub ahead of print. PMID: 36516082.
• Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LE, Mei MG, Popplewell LL, Siddiqi T, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam NR. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022 Nov 10;140(19):2024-2036. doi: 10.1182/blood.2022016747. PMID: 35914220
• Al Malki MM, Palmer J, Tsai N-C, Mokhtari S, Hui S, Tsai W, Aldoss I, Ali H, Aribi A, Cao T, Mei M, Sandhu KS, Siddiqi T, Forman SJ, Nakamura R, Marcucci G, Stein A, Wong JYC, Rosenthal J. Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Adv. 2022 Jul 26;6(14):4098-4106. doi: 10.1182/bloodadvances.2022007264. PMID: 35838754
• Kambhampati S, Mei MG, Godfrey J, Siddiqi T, Salhotra A, Chen R, Smith E, Popplewell LL, Herrera AF. PD-1 blockade after Avelumab in relapsed/refractory Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk 2022 Jun 6; S2152-2650(22)00185-9. doi: 10.1016/j.clml.2022.06.004. Online ahead of print. PMID: 35778267
• Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN guidelines insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2022. J Natl Compr Canc Netw. 2022 Jun;20(6):622-634. doi: 10.6004/jnccn.2022.0031. PMID: 35714675
• Kambhampati S, Saumoy M, Schneider Y, Pak S, Budde LE, Mei MG, Siddiqi T, Popplewell L, Wen YP, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam N. Cost effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B cell lymphoma. Blood. 2022 Jun 14:blood.2022016624. doi: 10.1182/blood.2022016624; online ahead of print. PMID: 35700381
• Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC. Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transplant Cell Ther. 2022 May 21:S2666-6367(22)01319-7. doi: 10.1016/j.jtct.2022.05.026. Online ahead of print. PMID: 35609867
• Siddiqi T, Coutre S, McKinney M, Barr PM, Rogers K, Mokatrin A, Valentino R, Szoke A, Deshpande S, Zhu A, Arango-Hisijara I, Osei-Bonsu K, Wang M, O’Brien S. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Lymphoma. 2022 Jul;63(7):1580-1588. doi: 10.1080/10428194.2022.2038372. Epub 2022 Feb 28. PMID: 35227147
• Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Fixed-duration ibrutinib plus venetoclax for first line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022 Jun 2;139(22):3278-3289. doi: 10.1182/blood.2021014488. PMID: 35196370
• Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Fuhrman RR, Treon SP. Venetoclax in previously treated Waldenstrom macroglobulinemia. J Clin Oncol 2022; 40: 63-71. PMID: 34793256
• Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 2022 Mar 24;139(12):1794-1806. doi: 10.1182/blood.2021011895. PMID: 34699592
• Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, Fertrin KY, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Ibrahim I, Kraut E, Leavitt AD, Lee A, Lee JT, Lim M, Mann J, Martin K, McMahon B, Moriarty J, Morton C, Ortel TL, Paschal R, Schaefer J, Shattil S, Siddiqi T, Sudheendra D, Williams E, Hollinger L, Nguyen MQ. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Oct 15;19(10):1181-1201. doi: 10.6004/jnccn.2021.0047. PMID: 34666313
• Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021 Oct 7: JCO2100807. doi: 10.1200/JCO.21.00807. Online ahead of print. PMID: 34618601
• Siddiqi T, Wang X, Blanchard MS, Wagner JR, Popplewell LL, Budde LE, Stiller TL, Clark MC, Lim L, Vyas V, Brown CE, Forman SJ. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021 Oct 26;5(20):4059-4063. doi: 10.1182/bloodadvances.2020004106. PMID: 34492703
• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021 Oct 26;5(20):4149-4155. doi: 10.1182/bloodadvances.2020003848. PMID: 34478487
• Woyach J, Tedeschi A, Munir T, Siddiqi T, Hillmen P, Byrd JC, Ghia P, Mulligan SP, Dai S, Amaya-Chanaga CI, Dean JP, O'Brien SM, Barr PM. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1957871. Online ahead of print. PMID: 34384312
• Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisnewski P, Patel K, Shadman M, Park B, Danilov AV. The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clin Cancer Res. 2021 Jun 24:clincanres.3993.2020. doi: 10.1158/1078-0432.CCR-20-3993. Online ahead of print. PMID: 34168050
• Sadras T, Martin M, Kume K, Robinson ME, Saravanakumar S, Lenz G, Chen Z, Song JY, Siddiqi T, Oksa L, Knapp AM, Cutler J, Cosgun KN, Klemm L, Ecker V, Winchester J, Ghergus D, Soulas-Sprauel P, Kiefer F, Heisterkamp N, Pandey A, Ngo V, Wang L, Jumaa H, Buchner M, Ruland J, Chan W-C, Meffre E, Martin T, Müschen M. Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Mol Cell. 2021 May 20;81(10):2094-2111.e9. doi: 10.1016/j.molcel.2021.03.043. Epub 2021 Apr 19. PMID: 33878293
• Abramson JS, Siddiqi T, Garcia J, Dehner C, Kim Y, Nguyen A, Snyder S, McGarvey N, Gitlin M, Pelletier C, Jun MP. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021 Mar 23;5(6):1695-1705. doi: 10.1182/bloodadvances.2020003531. PMID: 33720336
• Danilov AV, Spurgeon SE, Siddiqi T, Quinson A-M, Maier D, Smith D, Brown JR. A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. Invest New Drugs. 2021 Aug;39(4):1099-1105. doi: 10.1007/s10637-020-01056-4. Epub 2021 Mar 8. PMID: 33683501

Chapters:

• Siddiqi T. Chronic lymphocytic leukemia: Biology and Treatment. Siddiqi T. (2021) Chronic Lymphocytic Leukemia (CLL): Biology and Therapy. In: Pullarkat V., Marcucci G. (eds) Biology and Treatment of Leukemia and Bone Marrow Neoplasms. Cancer Treatment and Research, vol 181. Springer, Cham. https://doi.org/10.1007/978-3-030-78311-2_8